BITIA, new software for the investigation of cancerNovember 15, 2004NorayBio, a bioinformatics company located at the Bizkaia Technological Park (Basque Country) and specialising in developing software for the biosciences, has launched a new software for cancer research on to the market - BITIA, primarily aimed at research centres and cancer wards in hospitals. BITIA aims to help oncologists to answer the question that has been around for some time: Why is it that two patients with very similar pathology profiles respond in distinct ways to treatment? It is in the genes that the answer has been looked for and recent studies have revealed that the differentiated expression of some genes is involved in the risk of developing metastasis in some kinds of cancer. The BITIA software establishes relations between genic data and clinical data of cancer patients, providing new prognostic factors. In this way, BITIA aims to be a support tool for oncologists when taking decisions. BITIA has been designed and developed by NorayBio in collaboration with the Professor of Oncology and Palliative Medicine at the Autonomous University of Madrid and the Cancer Medical Service at the La Paz University Hospital, directed by Professor Dr. Manuel Gonzalez Bar'łn. The involvement in this project of a multidisciplinary team of cancer specialists, molecular biologists, software engineers and statisticians has enabled the development of an easy-to-use and powerful tool for the scientific and medical community. BITIA also optimises the commercial possibilities of NorayBio, which currently has two other software owners in the field of biopharmaceutical research: CacoReady SoftwareTM, for the study of intestinal absorption of compounds "in vitro", and Noraymet MicrosomeTM, involved in studies "in vitro" of liver metabolism with microsomes. Elhuyar Fundazioa |
|||||||||||||||||||||
| Related Cancer Current Events and Cancer News Articles U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. SNM applauds House action to build medical isotopes reactor in the US SNM applauds the U.S. House of Representatives for its passage of H.R. 3276-the American Medical Isotopes Production Act of 2009. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. New finding suggests prostate biopsy is not always necessary Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy. PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. Scientists visualize how bacteria talk to one another Using imaging mass spectrometry, researchers at the University of California, San Diego have developed tools that will enable scientists to visualize how different cell populations of cells communicate. Findings show nanomedicine promising for treating spinal cord injuries Researchers at Purdue University have discovered a new approach for repairing damaged nerve fibers in spinal cord injuries using nano-spheres that could be injected into the blood shortly after an accident. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. Breast density associated with increased risk of cancer recurrence A new study finds that women treated for breast cancer are at higher risk of cancer recurrence if they have dense breasts. Published in the December 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study's results indicate that breast cancer patients with dense breasts may benefit from additional therapies following surgery, such as radiation. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||